Citations 1
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal?
Mohan, Meera, Radhakrishnan, Sabarinath, Katodritou, Eirini , Fonseca, Rafeal, Mohan, Meera , Mohan, Meera , Katodritou, Eirini , Radhakrishnan, Sabarinath Venniyil , Schinke, Carolina
American Journal of Hematology | January 27, 2026 | Volume: 101 | Issue: 5 | Pages: 1141-1147
